Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Novartis's Entresto Doesn't Impress In 1Q; Orphan Drug Fails In PhIII

This article was originally published in Scrip

Executive Summary

Novartis AG's newly launched heart failure drug Entresto (valsartan/sacubitril), which has been dubbed the company's next blockbuster product, missed the mark in the first quarter of the year, posting sales more than $10m below analyst forecasts.

Advertisement

Related Content

Entresto US Sales Barriers Set To Be Removed By Strong Guidance
AstraZeneca Groomed Paul Hudson For His New Role … At Novartis
Novartis's Entresto Clears NICE But It’s a Close Run Thing

Topics

Advertisement
UsernamePublicRestriction

Register